AGLIANICO: Role of Glycation and Inflammation in Acute Ischemic Heart Disease
Study Details
Study Description
Brief Summary
This study requires the consecutive enrollment of 60 patients following the first event of acute myocardial infarction, evaluating B-Cell Activating Factor (BAFF) and methylglyoxal (MGO) levels in the acute setting (pre-reperfusion) and 3 months after reperfusion.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This study requires the consecutive enrollment of 60 patients at admission for first acute myocardial infarction. At enrollment, before reperfusion, a blood sample is obtained to measure B-Cell Activating Factor (BAFF) and methylglyoxal (MGO) levels in the acute setting. This measure is then repeated at follow-up visit 3 months after reperfusion. The aim of the study is to identify specific subsets of patients and evaluate biomarkers variations.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| First Ischemic Cardiac Event Measurement of BAFF and MGO at hospitalization (before reperfusion) and after 3 months during follow-up |
Diagnostic Test: BAFF and MGO
measurement of BAFF and MGO levels before reperfusion and after 3 months
|
Outcome Measures
Primary Outcome Measures
- Identification of Inflammatory Biomarkers (BAFF) linked to ischemic event and outcome [Day 0]
elevation of BAFF levels
- Identification of Glycation Biomarkers (MGO) linked to ischemic event and outcome [Day 0]
elevation of MGO levels
Secondary Outcome Measures
- Identification of biomarkers variations (BAFF) complications and outcome [After 3 months]
variation of BAFF from baseline
- Identification of biomarkers variations (MGO) complications and outcome [After 3 months]
variation of MGO from baseline
Eligibility Criteria
Criteria
Inclusion Criteria:
-
hospitalization for first myocardial infarction (STEMI or NSTEMI)
-
age between 18 and 80
Exclusion Criteria:
-
uncompensated T2DM (HbA1c >53mmol/mol)
-
use of anti-CD20 treatment
-
chronic anti-inflammatory treatment for autoimmune disease (i.e. DMARDs, high dose FANS, cortisonic drugs)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Istituto Clinico Città Studi | Milano | Italy | 20131 |
Sponsors and Collaborators
- GEK Srl
- Istituto Clinico Città Studi
Investigators
- Principal Investigator: Michele Bianchi, MD, Istituto Clinico Città Studi
- Principal Investigator: Altin Palloshi, MD, Istituto Clinico Città Studi
Study Documents (Full-Text)
None provided.More Information
Publications
- Akhand AA, Hossain K, Mitsui H, Kato M, Miyata T, Inagi R, Du J, Takeda K, Kawamoto Y, Suzuki H, Kurokawa K, Nakashima I. Glyoxal and methylglyoxal trigger distinct signals for map family kinases and caspase activation in human endothelial cells. Free Radic Biol Med. 2001 Jul 1;31(1):20-30.
- Blackburn NJR, Vulesevic B, McNeill B, Cimenci CE, Ahmadi A, Gonzalez-Gomez M, Ostojic A, Zhong Z, Brownlee M, Beisswenger PJ, Milne RW, Suuronen EJ. Methylglyoxal-derived advanced glycation end products contribute to negative cardiac remodeling and dysfunction post-myocardial infarction. Basic Res Cardiol. 2017 Sep 1;112(5):57. doi: 10.1007/s00395-017-0646-x.
- Evans JDW, Dobbin SJH, Pettit SJ, Di Angelantonio E, Willeit P. High-Sensitivity Cardiac Troponin and New-Onset Heart Failure: A Systematic Review and Meta-Analysis of 67,063 Patients With 4,165 Incident Heart Failure Events. JACC Heart Fail. 2018 Mar;6(3):187-197. doi: 10.1016/j.jchf.2017.11.003. Epub 2018 Jan 10.
- Francis Stuart SD, De Jesus NM, Lindsey ML, Ripplinger CM. The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. J Mol Cell Cardiol. 2016 Feb;91:114-22. doi: 10.1016/j.yjmcc.2015.12.024. Epub 2015 Dec 29. Review.
- Khan MA, Schultz S, Othman A, Fleming T, Lebrón-Galán R, Rades D, Clemente D, Nawroth PP, Schwaninger M. Hyperglycemia in Stroke Impairs Polarization of Monocytes/Macrophages to a Protective Noninflammatory Cell Type. J Neurosci. 2016 Sep 7;36(36):9313-25. doi: 10.1523/JNEUROSCI.0473-16.2016.
- Mariathas M, Allan R, Ramamoorthy S, Olechowski B, Hinton J, Azor M, Nicholas Z, Calver A, Corbett S, Mahmoudi M, Rawlins J, Simpson I, Wilkinson J, Kwok CS, Cook P, Mamas MA, Curzen N. True 99th centile of high sensitivity cardiac troponin for hospital patients: prospective, observational cohort study. BMJ. 2019 Mar 13;364:l729. doi: 10.1136/bmj.l729.
- Zouggari Y, Ait-Oufella H, Bonnin P, Simon T, Sage AP, Guérin C, Vilar J, Caligiuri G, Tsiantoulas D, Laurans L, Dumeau E, Kotti S, Bruneval P, Charo IF, Binder CJ, Danchin N, Tedgui A, Tedder TF, Silvestre JS, Mallat Z. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med. 2013 Oct;19(10):1273-80. doi: 10.1038/nm.3284. Epub 2013 Sep 15.
- 2021AGLIANICO